search
Back to results

Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D

Primary Purpose

Idiopathic Thrombocytopenic Purpura

Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
Anti-D
Sponsored by
University of Aarhus
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Idiopathic Thrombocytopenic Purpura focused on measuring Idiopathic Thrombocytopenic Purpura, Treatment, Anti-D, Subcutaneous, Clinical evaluation, Platelet count, IVIG

Eligibility Criteria

1 Year - 14 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Idiopathic thrombocytopenic purpura (ITP)

Sites / Locations

  • Aalborg University Hospital, Department of Pediatrics
  • Skejby Hospital, Aarhus University Hospital, Department of Pediatrics
  • Amager Hospital, Department of Pediatrics
  • Rigshospitalet, Copenhagen University Hospital, Pediatric Clinic II
  • Esbjerg Hospital, Department of Pediatrics
  • Gentofte Hospital, Department of Pediatrics
  • Herning Hospital, Department of Pediatrics
  • Hjoerring Hospital, Department of Pediatrics
  • Holbæk Hospital, Department of Pediatrics
  • Hvidovre Hospital, Department of Pediatrics
  • Kolding Hospital Department of Pediatrics
  • Nykøbing F, Department of Pediatrics
  • Næstved Hospital, Department of Pediatrics
  • Odense University Hospital
  • Randers Hospital, Department of Pediatrics
  • Sønderborg Hospital, Department of Pediatrics
  • Viborg Hospital, Department of Pediatrics

Outcomes

Primary Outcome Measures

Clinical effect evaluated on clinical score scale before and after treatment at specified intervals

Secondary Outcome Measures

Platelet count

Full Information

First Posted
August 8, 2005
Last Updated
February 2, 2009
Sponsor
University of Aarhus
Collaborators
Kjaersgaard, Mimi, M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT00128882
Brief Title
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D
Official Title
Treatment of Idiopathic Thrombocytopenic Purpura in Children With Subcutaneously Administered Anti-D
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Aarhus
Collaborators
Kjaersgaard, Mimi, M.D.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to describe the effect of anti-D on symptoms and platelet count in children suffering from unexplainable low platelet counts, when anti-D is administered as an injection under the skin. The hypothesis is that the injection with anti-D under the skin is as effective as anti-D given in a vein.
Detailed Description
Background: Idiopathic thrombocytopenic purpura (ITP) in children is considered a benign hematological disease. The incidence is approximately 50 cases a year in Denmark. Approximately 25 % will experience chronic disease. Follow up and treatment of these patients is not centralized. The drug of choice is intravenous IgG (IVIG) for treatment of ITP. The side effects are flu-like symptoms, and in rare cases aseptic meningitis. Another option is intravenous anti-D, if the child is rhesus positive. Anti-D is primarily used in North America. The effect of Anti-D is comparable with IVIG when considering the time it takes to bring the platelet count above 50,000/μL. Anti-D also causes flu-like symptoms. Establishing an i.v. access is a disadvantage to both IVIG and anti-D. For both treatments mechanism of action is not finally described. Subcutaneous IgG substitution therapy is used for patients suffering from agammaglobulinaemia. It is therefore known, that immunoglobulin uptake is possible after subcutaneous administration. Subcutaneous anti-D has been tried in few patients suffering from chronic thrombocytopenia with positive results. IVIG treatment is expensive compared to anti-D. Treatment of a 20 kg child costs approximately 17,000 Dkr for IVIG and 2,500 Dkr. for anti-D. Hypothesis: Subcutaneous administered anti-D is as effective as IVIG/i.v. anti-D; Subcutaneous administered anti-D has fewer less severe side effects than IVIG/i.v. anti-D. Purpose: To document the effect of subcutaneous anti-D; Describe complications; Describe aspects of the mechanism of action. Material and Methods: Children are eligible if admitted to a pediatric department in Denmark for diagnosis, observation or treatment of acute or chronic ITP. Examination and diagnostic work up is similar throughout the country, but not identical. No specific tests are required for diagnosis. If treatment is indicated rhesus positive children are treated with subcutaneous anti-D. Rhesus negative children are treated according to local guidelines. Specified follow-up on all children is mandatory. For research purposes one blood sample form all children is collected, and from children, who receive medical treatment, several blood samples are collected. Analysis for changes in immunological signaling peptides will be performed with special attention to the mechanism of action of anti-D.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Idiopathic Thrombocytopenic Purpura
Keywords
Idiopathic Thrombocytopenic Purpura, Treatment, Anti-D, Subcutaneous, Clinical evaluation, Platelet count, IVIG

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Anti-D
Intervention Description
Subcutaneous injection
Primary Outcome Measure Information:
Title
Clinical effect evaluated on clinical score scale before and after treatment at specified intervals
Time Frame
day 0,1,3,6,14,30, 180,360
Secondary Outcome Measure Information:
Title
Platelet count
Time Frame
day 0, 1, 3, 6, 14, 30, 180, 360

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Idiopathic thrombocytopenic purpura (ITP)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mimi Kjaersgaard, MD
Organizational Affiliation
University of Aarhus, Clinical Institute, Department of Pediatrics
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Henrik Hasle, MD PhD
Organizational Affiliation
Skejby Hospital, University of Aarhus, Department of Pediatrics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aalborg University Hospital, Department of Pediatrics
City
Aalborg
ZIP/Postal Code
9100
Country
Denmark
Facility Name
Skejby Hospital, Aarhus University Hospital, Department of Pediatrics
City
Aarhus N
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Amager Hospital, Department of Pediatrics
City
Copenhagen S
ZIP/Postal Code
2300
Country
Denmark
Facility Name
Rigshospitalet, Copenhagen University Hospital, Pediatric Clinic II
City
Copenhagen Ø
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Esbjerg Hospital, Department of Pediatrics
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Facility Name
Gentofte Hospital, Department of Pediatrics
City
Gentofte
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Herning Hospital, Department of Pediatrics
City
Herning
ZIP/Postal Code
7400
Country
Denmark
Facility Name
Hjoerring Hospital, Department of Pediatrics
City
Hjoerring
ZIP/Postal Code
9800
Country
Denmark
Facility Name
Holbæk Hospital, Department of Pediatrics
City
Holbæk
ZIP/Postal Code
4300
Country
Denmark
Facility Name
Hvidovre Hospital, Department of Pediatrics
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
Facility Name
Kolding Hospital Department of Pediatrics
City
Kolding
ZIP/Postal Code
6000
Country
Denmark
Facility Name
Nykøbing F, Department of Pediatrics
City
Nykøbing F
ZIP/Postal Code
4800
Country
Denmark
Facility Name
Næstved Hospital, Department of Pediatrics
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Facility Name
Odense University Hospital
City
Odense C
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Randers Hospital, Department of Pediatrics
City
Randers
ZIP/Postal Code
8900
Country
Denmark
Facility Name
Sønderborg Hospital, Department of Pediatrics
City
Sønderborg
ZIP/Postal Code
6400
Country
Denmark
Facility Name
Viborg Hospital, Department of Pediatrics
City
Viborg
ZIP/Postal Code
8800
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D

We'll reach out to this number within 24 hrs